Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
995 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03913741 | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies(innovaTV 206) | completed | Phase 1 / Phase 2 | 23 | GenmabINDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02623751 | Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | completed | Phase 1 | 15 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT01667133 | A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 35 | Ariad PharmaceuticalsINDUSTRY | 1 | Jun 13, 2022 | clinicaltrials |
| NCT04653142 | A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors) | completed | Phase 1 | 18 | Boehringer IngelheimINDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT03172936 | Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | terminated | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 8 | May 3, 2022 | clinicaltrials |
| NCT02315066 | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | completed | Phase 1 | 174 | PfizerINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03000257 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | AbbVieINDUSTRY | 10 | Apr 14, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02354898 | A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 60 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02358395 | A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 12 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02641873 | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 4 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03366428 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | completed | Phase 1 | 51 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03563560 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia(AML) | completed | Phase 1 | 10 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02088112 | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 3 | Apr 4, 2022 | clinicaltrials |
| NCT03203876 | A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03910530 | A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | completed | Phase 1 | 18 | Incyte Biosciences Japan GKINDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02493751 | A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) | completed | Phase 1 | 55 | PfizerINDUSTRY | 3 | Feb 18, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
| NCT03248843 | A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03696771 | Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT02096666 | A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects | completed | Phase 1 / Phase 2 | 11 | AmgenINDUSTRY | 1 | Dec 28, 2021 | clinicaltrials |
| NCT02189174 | Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 3, 2021 | clinicaltrials |
| NCT03497429 | A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors | completed | Phase 1 | 9 | TakedaINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT01750918 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 166 | Novartis PharmaceuticalsINDUSTRY | 8 | Oct 29, 2021 | clinicaltrials |
| NCT03752177 | A Study of LY3415244 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03745807 | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | completed | Phase 1 | 3 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 4, 2021 | clinicaltrials |
| NCT02746952 | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia(CALM) | completed | Phase 1 | 25 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 1, 2021 | clinicaltrials |
| NCT04071262 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | completed | Phase 1 | 6 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 21, 2021 | clinicaltrials |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 16, 2021 | clinicaltrials |
| NCT02948348 | Study to Nivolumab Following Preoperative Chemoradiotherapy | unknown | Phase 1 / Phase 2 | 90 | Takayuki YoshinoOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02851004 | Special Combination of BBI608 and Pembrolizumab | terminated | Phase 1 / Phase 2 | 55 | Takayuki YoshinoOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT04496089 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC(ZIRDAC-JP) | completed | Phase 1 | 6 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02177682 | Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 11, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT02992483 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 3, 2021 | clinicaltrials |
| NCT03086239 | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer | completed | Phase 1 | 29 | AbbVieINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma | terminated | Phase 1 | 8 | AbbVieINDUSTRY | 7 | Jul 26, 2021 | clinicaltrials |
| NCT02715531 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | completed | Phase 1 | 243 | Hoffmann-La RocheINDUSTRY | 7 | Jul 9, 2021 | clinicaltrials |
| NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT02096614 | Investigator Initiated Phase 1 Study of TBI-1201 | completed | Phase 1 | 18 | Mie UniversityOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT02143635 | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 8 | May 21, 2021 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials